GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001063118 | Oral cavity | OSCC | epithelial cell migration | 174/7305 | 357/18723 | 1.04e-04 | 7.70e-04 | 174 |
GO:00018437 | Oral cavity | OSCC | neural tube closure | 52/7305 | 88/18723 | 1.06e-04 | 7.84e-04 | 52 |
GO:00069706 | Oral cavity | OSCC | response to osmotic stress | 50/7305 | 84/18723 | 1.11e-04 | 8.15e-04 | 50 |
GO:000974320 | Oral cavity | OSCC | response to carbohydrate | 128/7305 | 253/18723 | 1.11e-04 | 8.16e-04 | 128 |
GO:006082810 | Oral cavity | OSCC | regulation of canonical Wnt signaling pathway | 128/7305 | 253/18723 | 1.11e-04 | 8.16e-04 | 128 |
GO:00002889 | Oral cavity | OSCC | nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay | 36/7305 | 56/18723 | 1.12e-04 | 8.24e-04 | 36 |
GO:00170155 | Oral cavity | OSCC | regulation of transforming growth factor beta receptor signaling pathway | 71/7305 | 128/18723 | 1.14e-04 | 8.34e-04 | 71 |
GO:00325707 | Oral cavity | OSCC | response to progesterone | 26/7305 | 37/18723 | 1.15e-04 | 8.35e-04 | 26 |
GO:000195416 | Oral cavity | OSCC | positive regulation of cell-matrix adhesion | 37/7305 | 58/18723 | 1.15e-04 | 8.35e-04 | 37 |
GO:004352518 | Oral cavity | OSCC | positive regulation of neuron apoptotic process | 37/7305 | 58/18723 | 1.15e-04 | 8.35e-04 | 37 |
GO:00316632 | Oral cavity | OSCC | lipopolysaccharide-mediated signaling pathway | 38/7305 | 60/18723 | 1.17e-04 | 8.46e-04 | 38 |
GO:009013218 | Oral cavity | OSCC | epithelium migration | 175/7305 | 360/18723 | 1.18e-04 | 8.54e-04 | 175 |
GO:00601356 | Oral cavity | OSCC | maternal process involved in female pregnancy | 39/7305 | 62/18723 | 1.19e-04 | 8.54e-04 | 39 |
GO:190307815 | Oral cavity | OSCC | positive regulation of protein localization to plasma membrane | 39/7305 | 62/18723 | 1.19e-04 | 8.54e-04 | 39 |
GO:004390319 | Oral cavity | OSCC | regulation of biological process involved in symbiotic interaction | 44/7305 | 72/18723 | 1.20e-04 | 8.57e-04 | 44 |
GO:00456006 | Oral cavity | OSCC | positive regulation of fat cell differentiation | 41/7305 | 66/18723 | 1.20e-04 | 8.60e-04 | 41 |
GO:007252120 | Oral cavity | OSCC | purine-containing compound metabolic process | 199/7305 | 416/18723 | 1.34e-04 | 9.53e-04 | 199 |
GO:005086315 | Oral cavity | OSCC | regulation of T cell activation | 161/7305 | 329/18723 | 1.44e-04 | 1.02e-03 | 161 |
GO:000915020 | Oral cavity | OSCC | purine ribonucleotide metabolic process | 178/7305 | 368/18723 | 1.45e-04 | 1.02e-03 | 178 |
GO:00322006 | Oral cavity | OSCC | telomere organization | 85/7305 | 159/18723 | 1.47e-04 | 1.04e-03 | 85 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TG | SNV | Missense_Mutation | rs201480815 | c.3416N>T | p.Ser1139Leu | p.S1139L | P01266 | protein_coding | tolerated(0.14) | benign(0) | TCGA-A1-A0SK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
TG | SNV | Missense_Mutation | | c.4662G>T | p.Trp1554Cys | p.W1554C | P01266 | protein_coding | deleterious(0.01) | benign(0.123) | TCGA-A1-A0SP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | | SD |
TG | SNV | Missense_Mutation | | c.4882N>T | p.Asp1628Tyr | p.D1628Y | P01266 | protein_coding | deleterious(0) | possibly_damaging(0.861) | TCGA-A2-A04W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
TG | SNV | Missense_Mutation | | c.3133N>A | p.Gly1045Arg | p.G1045R | P01266 | protein_coding | tolerated(0.13) | benign(0.007) | TCGA-A2-A25B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | PD |
TG | SNV | Missense_Mutation | | c.5223N>C | p.Gln1741His | p.Q1741H | P01266 | protein_coding | deleterious(0.02) | probably_damaging(0.994) | TCGA-A2-A25B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | PD |
TG | SNV | Missense_Mutation | rs773795717 | c.4645C>T | p.Arg1549Trp | p.R1549W | P01266 | protein_coding | deleterious(0.05) | benign(0.232) | TCGA-A7-A13E-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | bevacizumab | PD |
TG | SNV | Missense_Mutation | novel | c.1093N>A | p.Ala365Thr | p.A365T | P01266 | protein_coding | tolerated(0.44) | benign(0) | TCGA-A7-A26I-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
TG | SNV | Missense_Mutation | rs146594373 | c.4268N>A | p.Arg1423His | p.R1423H | P01266 | protein_coding | tolerated(0.55) | benign(0.001) | TCGA-A8-A06O-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | letrozole | SD |
TG | SNV | Missense_Mutation | | c.746G>A | p.Gly249Asp | p.G249D | P01266 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A8-A07L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | | CR |
TG | SNV | Missense_Mutation | | c.3746N>T | p.Cys1249Phe | p.C1249F | P01266 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A8-A08F-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | | RETINOIDS | | 12182039 |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | | FDG | FLUDEOXYGLUCOSE-F18 | 10452315 |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | | BISPECIFIC ANTIBODY | | 10433080 |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | | PHENYTOIN | PHENYTOIN | 3935423 |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | | PREDNISONE | PREDNISONE | 2745931 |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | | ALL-TRANS-RETINOIC ACID | | 10946899 |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | | TGFBETA1 | | 10770487,10194419 |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | | RETINOIC ACID | | 11563543 |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | | PREDNISOLONE | PREDNISOLONE | 3427792,8636270 |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | | AMIODARONE | AMIODARONE | 8778159 |